Related Experiment Videos

Kappa-opioid receptor binding varies inversely with tumor grade in human gliomas

E C Pan1, L M Bohn, M M Belcheva

  • 1E. A. Doisy Department of Biochemistry and Molecular Biology, St. Louis University Health Sciences Center, Missouri 63110-0250, USA.

Cancer
|January 5, 1999
PubMed
Abstract

Insights

Human brain tumors show varying kappa-opioid receptor levels. Glioblastoma multiforme has the least binding, suggesting potential for diagnosis and treatment stratification.

Area of Science:

  • Neuro-oncology
  • Molecular Pharmacology
  • Neuroscience

Background:

  • Opioid agonists inhibit neural tumor cell proliferation.
  • Opioid antimitogenic effects are mediated by opioid receptors.
  • Investigating opioid receptor levels in human brain tumors is of interest.

Purpose of the Study:

  • To determine kappa-opioid receptor levels in human brain tumors.
  • To assess the correlation between receptor levels and tumor grade.
  • To explore the clinical utility of opioid receptor stratification.

Main Methods:

  • Evaluated kappa-opioid receptor binding in 30 human brain tumor specimens obtained during craniotomy.
  • Utilized homologous competition binding curves with the kappa1-selective radioligand [3H]U69,593.
  • Estimated dissociation constant (Kd) and maximum binding capacity (Bmax) values.

Main Results:

  • Receptor binding density was highest in nonneoplastic brain tissue.
  • Lower receptor binding density was observed in Grade 2 and 3 astrocytomas.
  • Glioblastoma multiforme exhibited the lowest kappa-opioid receptor binding density.

Conclusions:

  • Opioid receptor levels differ significantly across human brain tumor grades.
  • Stratification based on opioid receptor binding may aid in distinguishing glioblastoma multiforme from lower-grade astrocytomas.
  • These findings suggest potential clinical utility for opioid receptor analysis in glioma diagnosis and treatment planning.

Related Concept Videos